Clinical trial NCT01193699: Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera
Official title: An Open-label, Prospective, Multicentre, Phase I/II Dose Escalation Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Efficacy of P1101, PEG-Proline-Interferon Alpha-2b in Patients With Polycythaemia Vera
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Polycythemia Vera
Lead sponsor: AOP Orphan Pharmaceuticals AG
Sponsor class: INDUSTRY
First posted: 2010-09-02
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is the identification of the maximum tolerated dose (MTD) of the investigational medicinal product. Moreover the safety and tolerability will be assessed and an exploratory analysis of efficacy and biomarker modulation will be performed.


Eligibility criteria: Inclusion Criteria:

1. Written informed consent obtained prior to any study specific screening activities and able to comply with this protocol.
2. Patients age ≥18 years
3. Confirmed diagnosis of PV according to either the WHO criteria (2008, appendix 6) or the PSVG (appendix 7) criteria plus JAK-2 positivity, including newly diagnosed, pre-treated and on cytoreductive therapy.
4. Eastern Cooperative Oncology Group performance status ≤ 2
5. If female of childbearing potential - have a negative urine pregnancy test result within 7 days prior to the scheduled first application of investigational product and agree to employ adequate birth control measures for the duration of the study.

Exclusion criteria:

1. Diagnosis of any other myeloproliferative disorder
2. Any clinically significant illness or surgery within 4 weeks prior to dosing
3. Systemic infections, e.g. hepatitis B, hepatitis C, or HIV at screening
4. Uncontrolled hypertension (systolic \> 150 mmHg and diastolic \> 100 mmHg, or clinically significant (i.e. active) cardiovascular disease: CVA/stroke (≤ 3 months prior to enrolment), myocardial infarction (≤ 3 months prior to enrolment), significant coronary artery stenosis, unstable angina, New York Heart Association (NYHA) Class 2 or greater Congestive heart failure, or serious cardiac arrhythmia requiring medication.
5. Previous treatment with Interferon for PV
6. Concurrent treatment with cytoreductive agents other than Hydroxyurea and investigational agents of any type
7. History of malignant disease, including solid tumours and haematological malignancies (except basal cell and squamous cell carcinomas of the skin and carcinoma in situ of the cervix that have been completely excised and are considered cured) within the last 3 years
8. History of severe allergic (like anaphylaxis) or hypersensitivity reactions (like angioedema), any known or suspected intolerance to the investigational product.
9. Use of any investigational drug or participation in any investigational drug study within the last 4 weeks
10. Clinically significant history or known presence of psychiatric disorders, including but not limited to depression, anxiety and sleep disorders
11. Organ transplant, past or planned
12. Inadequate liver function defined by serum (total) bilirubin \> 2,5 x ULN and/ or AST and ALT \> 2,5 x ULN
13. Clinically significant ECG findings
14. History of renal disease requiring haemodialysis or seizure disorder requiring anticonvulsant therapy
15. Pregnant or lactating females (pregnancy test to be assessed within 7 days prior to study treatment start)
16. Acute or chronic infections or autoimmune diseases (collagen diseases, polyarthritis, immune thrombocythemia, thyroiditis, psoriasis, lupus nephritis or any other autoimmune disorder).

Primary outcomes:
measure: Maximum tolerated dose (MTD)
timeFrame: The incidence of dose limiting toxicities (DLTs), which define the MTD are assessed continously until achievement of MTD.
Secondary outcomes:
Other outcomes:
Locations:
city: Innsbruck
country: Austria
state: Tirol
city: Wels
country: Austria
state: Upper Austria
city: Salzburg
country: Austria
city: Vienna
country: Austria
city: Vienna
country: Austria
city: Vienna
country: Austria
Study officials:
affiliation: AOP Orphan Pharmaceuticals AG
name: Barbara Grohmann-Izay, MD
role: STUDY_DIRECTOR
References:
citation: Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, Greil R. Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015 Oct 8;126(15):1762-9. doi: 10.1182/blood-2015-04-637280. Epub 2015 Aug 10.